BQST — Bioquest Share Price
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | n/a | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | n/a | ||
Price to Sales | n/a | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | n/a | ||
Return on Equity | n/a | ||
Operating Margin | n/a |
Financial Summary
Year End 30th Apr | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Bioquest Corp. is primarily focused on acquiring companies in the green energy sector. The Company has executed a letter of intent to acquire all of the issued and outstanding shares of Progressus Clean Technologies, Inc. (Progressus), which is a private company. Progressus is a venture stage green technology company focused on the development of hydrogen generation and separation technologies. Progressus owns the rights to intellectual property that enables the extraction of dilute amounts of hydrogen at purity from a various gas stream. The Company has not generated any revenue.
Directors
- Thomas Hemingway CHM (65)
- Michael Krall PRE (69)
- David Noyes CFO (78)
- Jeffery Donnell EVP (70)
- Pamela Daily CMO (70)
- Robert Orbach IND (67)
- Last Annual
- April 30th, 2022
- Last Interim
- July 31st, 2022
- Incorporated
- May 17th, 2011
- Public Since
- September 26th, 2013
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Pink Sheets on Nasdaq
- Shares in Issue
- 11,485,320

- Address
- 4570 CAMPUS DRIVE #23, NEWPORT BEACH, NEWPORT BEACH, 92660
- Web
- https://www.bioquestcorp.com/
- Phone
- +1 4182647134
- Auditors
- L J Soldinger Associates, LLC
Upcoming Events for BQST
Similar to BQST
Acacia Diversified Holdings
Pink Sheets on Nasdaq
Acusphere
Pink Sheets on Nasdaq
Soul Biotechnology
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
FAQ
As of Today at 13:04 UTC, shares in Bioquest are trading at $1.94. This share price information is delayed by 15 minutes.
Shares in Bioquest last closed at $1.94 and the price had moved by +273.08% over the past 365 days. In terms of relative price strength the Bioquest share price has outperformed the S&P500 Index by +226.57% over the past year.
There is no consensus recommendation for this security.
Bioquest does not currently pay a dividend.
Bioquest does not currently pay a dividend.
Bioquest does not currently pay a dividend.
To buy shares in Bioquest you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.94, shares in Bioquest had a market capitalisation of .
Here are the trading details for Bioquest:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: BQST
Based on an overall assessment of its quality, value and momentum Bioquest is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bioquest. Over the past six months, its share price has outperformed the S&P500 Index by +1705.84%.
As of the last closing price of $1.94, shares in Bioquest were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Bioquest PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.94.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Bioquest's management team is headed by:
- Thomas Hemingway - CHM
- Michael Krall - PRE
- David Noyes - CFO
- Jeffery Donnell - EVP
- Pamela Daily - CMO
- Robert Orbach - IND